Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Global cancer statistics

2011 • 55,498 citations

Global Cancer Statistics, 2002

2005 • 17,966 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Evaluation of survival data and two new rank order statistics arising in its consideration.

1966 • 7,595 citations

Analysis of Survival Data

1984 • 6,206 citations

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

1993 • 5,539 citations

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1999 • 4,973 citations

Applied Longitudinal Analysis

2011 • 4,411 citations

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

2003 • 2,723 citations

Renal-Cell Carcinoma

1996 • 2,232 citations

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

2003 • 1,939 citations

Mutations of the VHL tumour suppressor gene in renal carcinoma

1994 • 1,719 citations

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

2005 • 1,630 citations

Discrete Sequential Boundaries for Clinical Trials

1983 • 1,584 citations

Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

2002 • 1,471 citations

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2006 • 1,204 citations

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

1998 • 962 citations

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

1996 • 886 citations

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

2003 • 860 citations

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 • 801 citations

Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

2003 • 778 citations

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

2003 • 766 citations

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

2003 • 634 citations

SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA

2000 • 610 citations

Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

2002 • 603 citations

Immunotherapy for advanced renal cell cancer

2004 • 587 citations

Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

2005 • 561 citations

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

1999 • 512 citations

Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial

1999 • 506 citations

General Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G)

2005 • 479 citations

Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer

1999 • 448 citations

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

2000 • 438 citations

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

2003 • 380 citations

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

2005 • 358 citations

Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma

2000 • 271 citations

Novel approaches in the therapy of metastatic renal cell carcinoma

2005 • 222 citations

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

1998 • 196 citations

Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.

2003 • 194 citations

Analysis of Survival Data.

1986 • 134 citations

Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

2006 • 96 citations

Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial

2005 • 90 citations

Doing Data Analysis with the Multilevel Model for Change

2003 • 30 citations